Orforglipron Significantly Lowers HbA1c in Two Additional T2D Trials
Orforglipron Significantly Lowers HbA1c in Two Additional T2D Trials Topline data from two phase 3 trials evaluating orforglipron, an oral GLP-1 receptor agonist, in patients with type 2 d…